CRISPR/Cas9

News

Editas axes two-thirds of its staff, including its CMO

Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.

News

After a no in sickle cell, NICE OKs Casgevy for thalassaemia

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it dow

R&D

Opportunity costs of gene therapies. Where do we go from her...

Over 30 gene therapies have received regulatory approval.

R&D

The innovative future of CRISPR tech

CRISPR-based therapies have moved from theory to reality, after the recent landmark approval of the first such treatment by the FDA.

News

Study finds hundreds of overlooked cancer drug targets

Researchers from the Wellcome Sanger Institute and partners have carried out a comprehensive analysis of cancer cells, identifying 370 ‘priority’ targets that could be use

R&D